Results 41 to 50 of about 41,228 (229)

Therapy for Aplastic Anemia [PDF]

Hematology, 2011
Abstract A 24-year-old man from Ecuador presents to your clinic with dyspnea on exertion, bruising, and petechiae. He is noted to be pancytopenic with ANC 430, hemoglobin 7.4 g/dL (reticulocyte count 0.9%), and platelets 18 000. His BM biopsy is hypocellular for age. Ultimately, he is diagnosed with severe aplastic anemia. He is the only
Eva C. Guinan, Amy E. DeZern
openaire   +3 more sources

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

eJHaem
Background Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive ...
Matthew Holt, Richard J. Kelly, Jilles M. Fermont, Soudeh Ansari, Marion Dahlke, Isabelle Brindel, Lynda Maafa, Flore Sicre deFontbrune, Régis Peffault deLatour   +8 more
doaj   +1 more source

A Novel Therapeutic Strategy for Bone Marrow Failure: Niche Rejuvenation Using Costal Cartilage‐Derived Stem Cells

Advanced Science, EarlyView.
CDSCs exhibit the potential to differentiate into endothelial cells, vascular pericytes, and osteoblasts. These differentiated cells are capable of secreting additional pro‐hematopoietic cytokines. Furthermore, CDSCs can inhibit apoptosis and reduce DNA damage in injured hematopoietic stem and progenitor cells (HSPCs, including RHSCs and RHPCs), while ...
Rui Dong, Zhiguo Ling, Pengyuan Fan, Debao Li, Jinsong Wang, Wenjiong Shi, Rui Zuo, Runfeng Chen, Xuemin Sun, Lang Xiao, Yushi Ran, Shucheng Huang, Yi Tian, Chao Zhang, Yuzhang Wu, Bing Ni, Yi Zhang   +16 more
wiley   +1 more source

Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience

American Journal of Hematology, EarlyView.
ABSTRACT Breakthrough hemolysis (BTH) is defined as a hemolytic exacerbation in a patient with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement inhibitors (CIs). In the current era of several terminal and proximal inhibitors, there are no guidelines for defining BTH and its severity, and clinical management is not standardized.
Bruno Fattizzo, Giacinto Luca Pedone, Elisabetta Metafuni, Eloise Beggiato, Valentina Giai, Esther Natalie Oliva, Antony Ricchiuti, Marta Bortolotti, Simona Raso, Daniela Carlino, Mara Memoli, Sofia Vecchi, Jennifer Vidler, Sukanya Gogoi, Shreya Goel, Anna Corby, Roochi Trikha, Sneha Balakrishnan, Francesco Passamonti, Anna Paola Iori, Simona Sica, Shreyans Gandhi, Wilma Barcellini, Austin Kulasekararaj   +23 more
wiley   +1 more source

CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL

Haematologica, 2012
Background Very severe aplastic anemia is characterized by a hypoplastic bone marrow due to destruction of CD34+ stem cells by autoreactive T cells. Investigation of the pathomechanism by patient-specific gene expression analysis of the attacked stem ...
Ute Fischer, Christian Ruckert, Bernd Hubner, Olaf Eckermann, Vera Binder, Tamam Bakchoul, Friedhelm R. Schuster, Sylvia Merk, Hans-Ulrich Klein, Monika Führer, Martin Dugas, Arndt Borkhardt   +11 more
doaj   +1 more source

Hepatitis-associated aplastic anemia from workout supplement: Rare but potentially fatal entity

SAGE Open Medical Case Reports, 2020
Hepatitis-associated aplastic anemia (HAAA) is a rare clinical syndrome characterized by bone marrow failure 1–3 months after development of hepatitis. Untreated, hepatitis-associated aplastic anemia has poor outcome and the mainstay of treatment remains
Sanjog Bastola, Ojbindra Kc, Sumesh Khanal, Alexandra Halalau   +3 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure Syndromes

American Journal of Hematology, EarlyView.
ABSTRACT Distinguishing inherited bone marrow failure (IBMF) from acquired aplastic anemia (aAA) at diagnosis is a major clinical challenge and is essential for appropriate treatment and patients' counseling. Genetic testing to exclude IBMF is frequently subject to delays of several months and may not be available in all centers and could not be ...
Eléonore Kaphan, Anouk Walter‐Petrich, Lise Larcher, Thierry Leblanc, Benedicte Bruno, Edouard Forcade, Cecile Renard, Arthur Sterin, Michael Loschi, Elodie Lainey, Jean Soulier, Caroline Kannengiesser, Gérard Socié, Régis Peffault de Latour, Mony Fahd, Jérome Lambert, Flore Sicre De Fontbrune   +16 more
wiley   +1 more source

Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease

Haematologica, 2014
Aplastic anemia is a life-threatening bone marrow failure disorder characterized by peripheral pancytopenia and marrow hypoplasia. The majority of cases of aplastic anemia remain idiopathic, although hematopoietic stem cell deficiency and impaired immune
Clara Bueno, Mar Roldan, Eduardo Anguita, Damia Romero-Moya, Beatriz Martín-Antonio, Michael Rosu-Myles, Consuelo del Cañizo, Francisco Campos, Regina García, Maite Gómez-Casares, Jose Luis Fuster, Manuel Jurado, Mario Delgado, Pablo Menendez   +13 more
doaj   +1 more source

Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C [PDF]

, 2016
Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin.
Broquetas, Teresa, Calleja Panero, José Luis, Campillo, Ana, Carrion, José A., Forns, Xavier, Lens Garcia, Sabela, Londoño Hurtado, María Carlota, Mariño, Zoe, Perello, Chrostoe, Revilla, Juan de la, Sánchez Tapias, José M. (José María), Urbano Ispizua, Álvaro   +11 more
core   +1 more source